explore -WSS

explore

author：comprehensive 2025-10-02 00:42:03 - browse：25

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

explore

WSS

The wait for US passports is creating travel purgatory and snarling summer plans

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Lupron, used to halt puberty in children, may cause lasting health problems

STAT wants to know your pick for a great summer read or listen

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

explore

explore

Wikipedia

Psychedelics group wrestles with new pharma identity

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Jerome Adams on the need for new antivirals for Covid

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Cancer drug shortages should be causing more outrage

The biotech scorecard for Q3: 15 stock

Hepatitis C has a cure — but many Americans still lack access to it

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Affirmative action in medical school literally saved lives

ASCO eve: Let’s set the table for this year's meeting

explore

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Addressing health care workers' trauma can help fight burnout

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Security flaws in third

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Citing H5N1 threat, CDC urges peak flu monitoring this summer

focus

explore

hotspot

focus